Eyal Zbeda
co-founding partner at Mobilion Ventures
Israel
Eyal Zbeda, co-founding partner at Mobilion Ventures is an active investor based in Israel. This profile covers what Eyal Zbeda backs, at which stage, and how founders can reach out in 2026.
Eyal Zbeda is a co-founding partner at Mobilion Ventures and Chairman of the Board at ZBEDA Group.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- Automotive & EV
- Location
- Israel
- Typical check
- $625K
How to reach Eyal Zbeda
Angels and operators like Eyal Zbeda reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Eyal Zbeda
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Eyal Zbeda invest in?
Eyal Zbeda invests in Automotive & EV, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Eyal Zbeda invest at?
Eyal Zbeda typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Eyal Zbeda's typical check size?
Eyal Zbeda typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Eyal Zbeda?
Unlock Eyal Zbeda's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.